Steve,
My wife is about to deliver so you can count me out this year. Here's the latest news from Inflazyme.
Attention Business Editors:
INFLAZYME PHARMACEUTICALS LTD. (VSE:IZP) ANNOUNCES
APPOINTMENT OF MR. IAN KEITH ANDERSON TO ITS BOARD OF DIRECTORS
VANCOUVER, Aug. 14 /CNW/ - Inflazyme Pharmaceuticals Ltd. (the
``Company''), announced today the appointment of Mr. Ian Keith Anderson as a
member of its Board of Directors. Mr. Anderson served previously as President
and/or Managing Director of a number of established biotechnology companies,
including Biomira Diagnostics Inc., Biomatrix Canada Inc. and Fison
Pharmaceuticals Inc. of Canada, a subsidiary of Fisons Corp Plc of the United
Kingdom.
Mr. Anderson brings to Inflazyme a wide range of knowledge and experience
in the management of high-growth pharmaceutical companies and marketing of
their products. His appointment to the Inflazyme Board marks a significant
milestone in the company's steady progress from a pharmaceutical start-up to a
mid-stage biopharmaceutical company with proprietary families of drugs to
combat a variety of major diseases.
Within this context, Mr. Robert Gayton, who served the company for two
years as a Director and functioned as its accounting advisor, has resigned in
order to expedite this transition to new Board Members with proven
international expertise in the pharmaceutical industry. In addition, subject
to VSE approval, the company granted 200,000 stock options priced at $1.70 to
its Board of Directors and Employees.
Inflazyme Pharmaceuticals Ltd. is a mid-stage biopharmaceutical company
with a number of revolutionary drugs for the treatment of all types of
inflammatory diseases. Inflazyme's lead anti-inflammatory drugs are Apanol
for the treatment of asthma; Tiesole, an anti-allergy drug; and Bispan for the
treatment of arthritis. The Company is also developing a proprietary anti-
cancer drug, and has signed an option agreement with Abbott Laboratories for a
license to distribute worldwide Inflazyme's Tuberculosis Diagnostic Kit, based
on Inflazyme's uniquely sensitive, state-of-the-art TB Antigen.
For more information on the Internet, including complete share price
updates (fifteen minute delay), please go to:
stockprofiles.com
Exemption from registration pursuant to Rule l2g3-2(b). Reg. #82-2317.
Included in standard & Poor's corporation records. The Vancouver Stock
Exchange has neither approved nor disapproved of the information contained
herein.
For further information: James King, Manager of Investor Relations, Phone (604) 733-5181, Fax (6O4) 733-5281, (800)
315-3660
13:30e 14-AUG-96 |
